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Abstract 
The purpose of this project was to develop a scaffold to contain hyperpolarization-
activated cyclic nucleotide gated (HCN) channel modified human mesenchymal stem cells 
(hMSCs), which would couple with cardiac myocytes, forming a biological pacemaking unit. 
The primary objectives of the scaffold were to prevent hMSC migration out of the scaffold, 
allow contact with neighboring myocytes to form gap junctions, and protect the hMSCs from 
damage during and after implantation. To do this, we designed a scaffold and chose materials 
that would meet these objectives. Through a detailed design process, our final design 
components included a stent-like structure made of Nitinol to provide structure yet remain 
flexible in the heart and an electrospun polyurethane sheath to encapsulate the hMSCs but still 
allow gap junction formation. To characterize the thickness of the polyurethane we completed a 
migration assay, which resulted in an ideal thickness achieved between 30 and 45-minute spin 
times. Our work on the design of the BioPacer has made progress towards achieving the above- 
mentioned objectives and autonomous cardiac pacing. 
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Chapter 1: Introduction 
 In a 2010 update on Heart Disease & Stroke Statistics the American Heart Association 
reported 831,300 deaths related to heart diseases within the past year. The United States alone 
spent $316.4 billion on expenses related to cardiovascular disease. Many of these problems are 
related to the electrical functions of the heart and are currently remedied by implanting an 
artificial pacemaker into the heart.1,2   
  Although electrical pacemakers do remedy many cardiovascular problems, they still 
have many limitations. Electronic pacemakers have a limited battery life, which ultimately leads 
to battery replacement and thus repeated surgeries. Electronic pacemaker could be severely 
displaced from their implanted location and could also be functionally impeded by machines 
such as MRI or CT scan equipment. Infections due to the pacemaker could also lead to removal 
of the pacemaker. A patient implanted with an electronic pacemaker also has restrictions in their 
day-to-day activities. Pacemakers are not a replacement for the autonomic pacing of the heart 
and thus create limitations on the physical exertion a patient can go through. It is also important 
to remember that pacemakers have to grow with the person. This becomes a concern for pediatric 
patients, whose age and size create several problems. Thus it is important to note that electrical 
pacemakers are a palliation rather than a permanent cure.3 
 Biological pacemakers represent an alternative that is much more biologically inert and 
has the potential to be a cure for the life of a patient. Biological pacemakers could be 
autonomically responsive in that they could have the ability to change with the patient’s 
physiological and emotional demands. The use of human mesenchymal stem cells (hMSCs) has 
great potential as a biological pacemaker. hMSCs transfected with a particular HCN gene have 
been proven to combine with cardiac myocytes to create a pacing unit that could aptly substitute 
for the natural pacing of the heart.3  
 However before stem cell therapy can be used as a cure to cardiovascular diseases, 
several obstacles must be overcome, such as the design and deliver of the cells. A scaffold must 
be designed that addresses issues such as cell migration, gap junction formation, mechanical 
strength, and compliance with surrounding tissue, autonomic response, and a minimally invasive 
implantation mechanism. To properly address these issues the team designed several experiments 
including: biological assays such as migration assays and Connexin 43 assays, mechanical tests 
such as uniaxial load testing and fatigue testing, and conducted significant research. Through 
their work the team developed a final design for a scaffold, which could be implanted through a 
minimally invasive procedure, to hold hMSCs in place and allow for the formation of gap 
junctions between the hMSCs and cardiac myocytes while complying with the hearts 
physiological changes.     
9 
 
Chapter 2: Literature Review 
!"#$%#&'($$
!"#$%"$#&'()*'+$)%",-).''
   The heart is a hollow organ that is located between the lungs and is positioned posterior 
to the sternum and the rib cartilages. The organ is divided into four sections as follows: The right 
and left atria, and the right and left ventricle.4 These four chambers are connected to several 
blood vessels. The structure of the heart is seen in Figure 1 below.5 
  
 
The chambers, vessels, and valves of the heart control the flow of blood through the heart and to 
the rest of the body. Deoxygenated blood first enters the heart through the inferior and superior 
vena cava and empties into the right atrium. The blood then flows through the atrioventricular 
valve and into the right ventricle. As the heart contracts it pumps the blood from the right 
ventricle through the pulmonary valve into the pulmonary artery to the lungs where it becomes 
oxygenated. The oxygenated blood enters back into the heart's left atrium through the pulmonary 
vein, and the subsequent opening of the mitral valve allows the blood to empty into the left 
ventricle. Another contraction causes the left ventricle to pump the oxygenated blood through the 
aortic valve, into the aorta and out to the rest of the body.6   
Figure 1: The chambers and valves of the heart.5 
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  Aside from the structure and blood flow of the heart it is also important to consider the 
mechanical functions of the heart.  Every day, an average adult heart pumps approximately 2,000 
gallons of blood.  The heart also beats an average of 100,000 times per day. Through the course 
of seventy years this adds up to more than 2.5 billion beats and 31 million gallons of blood.7 
These numbers could vary from person to person based on the person’s blood pressure, which is 
the pressure that the blood exerts on the walls of blood vessels as it circulates around the body.  
This pressure is controlled by three factors: blood volume, the peripheral resistance, and the 
cardiac rate. As the heart experiences systole (contraction) and diastole (relaxation) the pressure 
rises and falls respectively. When the heart undergoes diastole the average systemic pressure is 
80 mm Hg (millimeters of mercury) and the pressure averages 120 mm Hg during systole.6 
Higher or lower than average blood pressure rates could drastically impact the wear of a person’s 
heart.   
/0&%"#,%(0'+$)%",-)'
  The heart contracts and relaxes in response to the electrical stimuli generated within the 
hearts unique electrical system.  This system is controlled by the flow of ions though cells which 
results in an action potential. To better understand the mechanism of the majority of heart cells 
observe Figure 2.8 
  
 Phase 4 represents the normal resting state of 99% of cardiac myocytes. The cells remain in this 
potential stage until they are excited by a neighboring cell.  Phase 0, which is the excitation of 
the myocyte, occurs due to the influx of sodium ions (Na+) as fast Na+ ion channels open. There 
is a higher concentration of Na+ ions on the outside of the cells and thus the opening of these 
channels triggers what is called the depolarization phase as the ions flow into the cell. This phase 
causes the cell to fire an action potential.9,10    
 Phase 1 occurs when the Na+ channels are closed and K+ ions flow to the outside of the 
cell. This process re-polarizes the cell slightly; the cell does not further depolarize due to the 
inward flow of Ca+2 ions that negates the outward flow of the K+ ions. Phase 3, which is the 
rapid polarization of the cell, occurs when there is no longer an influx of Ca+2 ions while K+ ions 
are flowing out. Once the cell has gone back to its resting potential the K+ are closed and the cell 
Figure 2:" Ion flow during the phases of cardiac action potential".8 
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returns to Phase 4. The remaining 1% of heart cells, known as pacemaker cells, has the ability to 
generate their own action potentials.9,10    
 The autorhythmic pacemaker activity of these cells is created by a similar flow of ions as 
mentioned above. Figure 3B represents the flow of ions and there representative effects on the on 
the current within the cells.11 The key differences to note are that these cells do not have a resting 
potential like the other cells, this difference can be seen by comparing Figure 3A and 3B below. 
Figure 3B also shows that these cells gradually depolarize after an action potential and fire again 
once they have crossed their threshold potential. The ability of these cells to keep depolarizing 
and re-polarizing autonomously controls the natural pacemaker activity of the heart.11  
 This pacemaker activity mentioned above originates at the Sinoatrial node (SA node) in 
healthy hearts. The SA node is located in the right atrial wall close to the superior vena cava.  
The function of the node is to fire an action potential approximately 70 to 80 times per minute.  
The action potential from the SA node first travels to the contractile cells in the two atriums.  
From there it propagates to the Atrioventricular node (AV node).9,10   
 The AV node is another pacemaker region in the heart, often referred to as the secondary 
pacemaker. The AV node only generates an action potential 40 to 60 times per minute.  
Following the AV node the signal that propagated from the SA node travels down through the 
Bundle of His, through the Purkinje Fibers and around the ventricles.9,10 The conduction system 
of the heart in Figure 4 below.6  
 Similar to the AV node, the Bundle of His and the Purkinje Fibers all fire at slower rates 
individually when compared to the SA node. However, since gap junctions connect them all, the 
AV node, the Bundle of His, and the Purkinje Fibers assume the same rate as the SA node.  Gap 
junctions allow for electrical impulses to be passed from one cell to another without interruption 
through an electrical coupling of the cell. Gap junctions are channels that enable the flow of ions 
from one cell to another. This keeps the contraction and relaxation of the heart functioning in 
unison.6, 9, 10   
Figure 3: "Comparison of action potentials in ventricular muscle and diagram of the membrane 
potential of pacemaker tissue."11 
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  The SA node maintains a regular rhythm while still being able to adapt to physiological 
and emotional changes. Thus the malfunctioning of the SA node or a disturbance in the 
communication between the SA node and the AV node can lead to severe issues regarding the 
heart. 
)&'*+&,$-''".("/+&0$$
 Several of the cardiovascular diseases that affect many Americans are cardiac conduction 
disorders. The heart contracts in response to electrical stimuli that the heart's electrical system 
delivers in a sequential manner to facilitate the pumping of blood. In some patients however, the 
functionality of the heart's electrical system is disturbed causing erratic heart rates and rhythms 
as opposed to the regular, synchronized rates and rhythms caused by correctly sequenced 
conduction in a healthy heart.12 These abnormal heart rates and rhythms are called !""#$%#&'!(. 
 A variety of scenarios can result in an arrhythmia. The Sinoatrial (SA) node is the heart's 
natural pacemaker as it contains the cells that can independently depolarize the fastest. When the 
SA node fires at an abnormal rate or rhythm, the rest of the heart also follows that same 
abnormal pattern resulting in an arrhythmia.  In some cases, the normal conduction pathway in 
the heart is interrupted or "blocked" making it impossible for the electrical signal to propagate 
correctly through the heart. An arrhythmia can also occur after a myocardial infarction, where a 
portion of the heart that would normally be responsible for acting as a pacemaker or for 
propagating the electrical current dies, so the heart adopts an irregular rate or rhythm.12  
 Unfortunately, thousands of people in the United States alone are affected by 
arrhythmias. The latest estimate by the American Heart Association reports that in 2006, more 
than 36,800 death certificates in the United States mentioned cardiac arrhythmias as a primary or 
underlying cause of death, and more than 835,000 patients were discharged from hospitals for 
conditions relating to cardiac arrhythmias. In that same year, over $3.1 billion was paid to 
Medicare beneficiaries for treatment relating to cardiac arrhythmias.13  
Figure 4: Conduction system of the heart.6 
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 Many arrhythmias are life-threatening, for instance, ventricular tachycardia and 
ventricular fibrillation are extremely rapid or chaotic rhythms that completely impair the heart's 
ability to pump blood, ultimately causing damage to organs including the heart and brain.12 In 
rhythms such as atrial fibrillation, the quivering of the upper chambers of the heart does not 
allow the blood to flow from the atria to the ventricles as quickly as it should. As a result, clots 
can form in the stagnant blood, which can migrate from the heart into the lungs or brain causing 
a pulmonary embolism or a stroke, both of which are potentially fatal.12  
-'(+1+,+&2$3&,#/&4#'0$
 Many arrhythmias can be treated using an artificial electronic pacemaker. In addition to 
treating arrhythmias such as symptomatic bradycardia, ventricular tachycardia, atrial fibrillation, 
and the collection of arrhythmias known as sick sinus syndrome. Artificial pacemakers are also 
being used to treat conditions other than arrhythmias such as hypertrophic cardiomyopathy, 
neurocardiogenic syncope, and chronotropic incompetence14. Currently, pacemakers are also 
being used to assist patients with congestive heart failure or patients who have recently had an 
acute myocardial infarction.15  
 Pacemakers have two distinct parts: the pulse generator and the leads. The pulse 
generator is about the size of two half-dollar coins and typically weighs slightly more than one 
ounce. It contains a small computer and a battery that generates small electric impulses that can 
be delivered to the heart in order to stimulate it to contract. The impulses are delivered to the 
heart by thin, insulated wires called leads. Electrodes on the ends of the leads sense the heart's 
electrical activity and deliver the electrical impulse when the heart's rate and rhythm are 
abnormal.16 
3&,#/&4#'$5/62&7(&(+879$:+7+/&22.$57;&0+;#$<='>#'.$
 Over 600,000 new pacemakers are surgically implanted each year. The most common 
method for pacemaker implantation in adults is the endocardial or transvenous approach, which 
can take anywhere from two to five hours.15 In this method, the patient is given an antibiotic and 
a relaxant through an IV and is then given a local anesthetic to numb the area where the device 
will be inserted. A three to four inch incision is made underneath the patient's left clavicle and a 
small incision is made into a large vein, usually the subclavian vein. The leads are inserted into 
the vein, and the surgeon uses fluoroscopy to guide the leads to the heart and attach them to the 
muscle in the appropriate chamber of the heart. The other ends of the leads are then attached to 
the pulse generator, which is then tucked into the incision under the clavicle. The incision is then 
closed and the patient is monitored in the hospital overnight. Typically, after a period of two to 
three weeks, the patient is able to return to their normal physical activities.15 
14 
 
 
 Pacemaker implantation is an example of a minimally invasive surgery. The term 
"minimally invasive" was coined in 1984 when John EA Wickham included it in an article for 
the British Medical Journal. Since then, it has come to mean any surgery that is less invasive 
than an open surgery used for the same purpose or when there is minimal damage to the tissues 
at the point of entrance of the surgical instrument(s). Instead of exposing the organs, it is 
typically done through the skin or through some body cavity or natural orifice. Like pacemaker 
implantation, many other minimally invasive surgeries are carried out endovascularly. 
Endovascular surgeries are designed to access many regions of the body, including the heart, via 
major blood vessels. While endovascular surgeries were originally developed for diagnostic 
procedures, the development of balloons, stents and catheters have allowed for therapies in 
addition to diagnoses. These procedures involve the introduction of a catheter through a small 
puncture in the skin and into a large blood vessel. By injecting a radio-opaque dye, the surgeon 
can see the catheter and the blood vessels and can advance the catheter to the particular area of 
interest. Endovascular procedures can be performed by radiologists, neurologists, neurosurgeons, 
cardiologists or vascular surgeons.  
 Minimally invasive procedures have many obvious benefits. For example, unlike open 
surgeries, minimally invasive procedures only occasionally require the patient to undergo general 
anesthesia. Most procedures, including pacemaker implantation, only require localized 
anesthesia. As a result, patients who endure minimally invasive surgeries require shorter hospital 
stays or are even allowed to go home the very same day. The recovery time is less than that of 
traditional surgeries and, in general, the patient is subject to less pain and scarring and fewer 
post-surgery complications. Of course, all of these things do vary based on the specific 
procedure. Similarly, the implantation procedure and the recovery are dependent upon the type 
of pacemaker the patient receives.  
Figure 5: Types of pacemakers and their parts.17  
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 Pacemakers can have anywhere from one to three leads, depending on the type of 
pacemaker (Figure 5: Types of pacemakers and their parts.).17  Single-chamber pacemakers use 
one lead to stimulate either the atrium or the ventricle, while dual-chamber pacemakers use two 
leads (one in the atrium and one in the ventricle) to coordinate the function of both chambers. 
Biventricular pacemakers use three leads, one in the atrium and one in each ventricle. This is 
particularly useful in patients with heart failure, bundle branch blocks, or a history of cardiac 
arrest. Until recently, pacemakers were set to monitor the heart rate and begin pacing only when 
the heart rate fell below a predetermined rate (typically somewhere around 70 beats per minute). 
Now, most artificial pacemakers are capable of adjusting the pacing rate in response to exercise 
and other stresses by sensing differences in the patient's motion, breathing, temperature and other 
physiologic conditions. These are called rate responsive pacemakers, and while they are 
significantly more advanced than the pacemakers of fifty years ago, they often do not respond to 
the patient's needs appropriately. For instance, variations in breathing or body temperature may 
be signs of physical exertion, or it may just be a hot summer day.  
 Pacemakers also have other limitations that require further advancement. Many of these 
problems can be attributed to the limitations of the leads and the pulse generator. More 
specifically, the typical battery life is approximately eight to ten years; once the battery begins to 
fail, the entire implantation procedure must be repeated to replace the pulse generator. 
Furthermore, the leads may fail for many reasons including the loss of the insulating material, 
displacement of the electrodes, loss of or inappropriate stimulation, or fracture of the wires.14 
Perhaps the most important inadequacy is the fact that even pacemakers that incorporate the most 
recent technologies are often incapable of responding appropriately to physically or emotionally 
stressful situations. 
 To address these shortcomings, many studies have recently been done to look into the 
feasibility of making a biologically-based alternative to today's electronic pacemaker.  
?+828>+,&2$3&,#/&4#'0$$
 Numerous recent studies have been published that collectively illustrate a shift in the way 
researchers are looking to advance cardiac conduction therapies. Instead of investigating ways to 
improve current electronic therapies, many studies have been published recounting efforts to 
develop a biologically-based pacemaker to supplement, or ideally replace, artificial pacemakers. 
These methods have been aimed at either stimulating the heart's natural pacemaker (the SA node) 
or generating an ectopic focus (a group of cells other than the SA node that act as a pacemaker 
for the heart). So far, studies have generally employed one of three main strategies14:  
• gene transfer to existing myocytes  
• cellular transplantation 
• delivery of genetically modified cells to the heart  
 Many of the more successful studies utilize some variation of the third strategy in which 
cells that are modified to spontaneously produce pacemaker activity are delivered to the heart. In 
16 
 
particular, several studies have shown promising results by delivering cells that are genetically 
modified to over-express the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel 
HCN2.18,19,20 Studies have also shown that the use of genetically modified human mesenchymal 
stem cells (hMSCs) to create this spontaneous pacemaker activity has the potential to open up a 
whole new realm of possibilities for the treatment of cardiac conduction disorders. 14,21  
:#0#7,"./&2$<(#/$)#220$
 To address the issues surrounding artificial pacemakers, (human) mesenchymal stem 
cells (hMSCs) have been explored as a basis for the creation of a biological pacemaker cell. 
hMSCs are a type of stem cell that are characterized by their self-renewal and multipotency, 
meaning they have potential to differentiate into a number of cellular lineages such as osteocytes, 
chondrocytes, myocytes, adipocytes, stromal cells, and fibroblasts.22 Sources for MSCs include 
isolation from cartilage, periosteum (membranous surface on certain bones), synovium (non-
cartilaginous soft tissue lining), tendons, adipose tissue, muscle, fetal tissue, placental tissue, and 
umbilical cord blood.23,24,25 However, the most common site of MSC harvesting occurs at the 
bone marrow, where isolation from bone marrow aspirates is very efficient compared to other 
harvesting sites.26 Additionally, MSCs have low antigenicity as research has indicated that in 
experimentally transplanted hMSCs there was a lack of immune response and clearance.27 The 
combination of these characteristics, in addition to the absence of ethical considerations 
associated with embryonic stem cells restrictions has made MSCs an appealing option for use in 
cell or gene therapies, tissue regeneration, and anticancer treatments.28  
 The use of MSCs as a pacemaker cell was driven by research indicating that forced 
expression of a hyper-polarization activated cyclic nucleotide-gated channel (or HCN) in an in 
vivo model could generate a pacemaker current (If). This current is largely responsible for the 
diastolic depolarization and rhythm of the Sinoatrial node (SA node), 100 to 1000 fold greater 
than the native If.29,30 Additional research that supported the potential for MSCs for pacemaker 
function illustrates their ability to transfer dye and electrical current to other cell types (including 
myocytes), as well as the ability to form functional gap junctions among themselves and 
myocytes as indicated by their expression of the protein Connexin 43.31 This led to research that 
used hMSCs, transfected by electroporation using a viral vector, that is a genetically engineered 
virus used to delivery genetic information to a cell, containing an isoform of the HCN family 
(murine HCN2), to create a cardiac pacemaker.32 Specifically the HCN gene family is a set of 
protein channels that allows the passage of both sodium and potassium ions.33 In a normal 
cardiac pacemaker cell, such as those of a normal sinus node cell, phase 4 depolarization, or the 
spontaneous depolarization (pacemaker potential) that triggers the action potential will be 
propagated through the conducting system of the heart and cause cardiac contraction. The 
genetically modified MSCs with an HCN channel are unexcitable like these sinoatrial nodal cells 
because they do not express all the factors needed to generate its own action potential. These 
MSCs can be coupled with adjacent myocytes through gap junctions that provide a depolarizing 
17 
 
current and drive the myocytes toward an action potential. Ultimately, this produces a coupled 
pacemaker unit between the engineered MSC and the myocytes.32 
 Though this provides a platform for the use of modified undifferentiated MSCs as a 
biological pacemaker there are concerns that need to be addressed for its advancement. Little is 
known about longevity of the pacemaker function and the MSCs’ ability to remain in an 
undifferentiated state. In addition, cell migration is a key issue as it is important to keep the 
delivered cells to the appropriate region. Should the cells migrate and delocalize from the target 
area then the pacemaker function may be compromised. 34 
@2#,('806+77+7>$
 The problem of stem cell migration can be addressed by using a scaffold that contains the 
stem cells. There are many types of scaffolds and many methods to create them, however 
electrospun scaffolds are becoming increasingly popular.  Electrospinning is a method of 
polymer processing that uses an electrically charged jet of polymer solution to create fibers with 
diameters in the nanometer to micrometer range (Figure 6). The polymer solution is placed into a 
syringe and a high voltage is applied to the tip of the needle (typically anywhere from 0 to 40 
kV). The polymer liquid flows at a set rate from the syringe and becomes charged as it leaves the 
needle. These charges cause the droplets to repel one another resulting in the formation of cone 
at the tip of the needle where the polymer is "whipped" and stretched out into long fibers. This 
whipping motion creates many thin fibers that continue being stretched until they are deposited 
onto a grounded collecting surface, or mandrel, to which they are attracted.  
 There are many factors that control the diameter of the fibers and the porosity of the 
material. For instance, adjusting the distance from the tip of the needle to the mandrel or 
adjusting the applied voltage will both affect the diameter of the fibers. In addition, longer spin 
times create thicker materials with smaller pores. Although electrospinning is an attractive option 
for the creation of porous materials that still have a certain degree of structural integrity, it is not 
always consistent in that the same spinning conditions can sometimes create materials with 
different properties (fiber diameter, porosity, thickness, etc.).  
 Still, there are many advantages to electrospinning. First, the random mesh-like structure 
formed by the electrospun nanofibers closely resembles the natural extracellular matrix which 
then enables cell attachment (Figure 7).35 Second, as previously stated, the porous materials can 
Figure 6: Schematic of the electrospinning process.  
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be created in a relatively efficient and inexpensive way. In addition, a variety of solvents allow 
for electrospinning to be completed at room temperature as opposed to the high temperatures 
required for melt spinning. This eliminates the problem of degradation, either of the polymer 
itself or any drug or biomolecules that may be incorporated into the polymer. Finally, 
electrospinning offers flexibility by using mandrels of different shapes that result in materials 
that vary in size and shape, such sheets and tubes. These qualities make electrospinning a viable 
option for the creation of a scaffold for use in a biological pacemaker. 
382.='#("&7#$
 One of the major aspects of designing a scaffold is deciding on the material to be used. 
The material must be able to comply with the contraction of the heart tissue, yet strong enough to 
withstand the cyclic loading without excessive permanent deformation or breakage. Furthermore, 
the pore size of the material must be controlled so that it is large enough to allow gap junction 
formation between the hMSCs and the myocytes, which exist on opposite sides of the material, 
but also small enough so that it does not allow cell migration into or out of the scaffold. The 
chosen material must also be biocompatible to minimize the immune response incited by the 
implantation. In addition, having a non-degradable material will increase the long-term durability 
of the scaffold, another necessary quality. A material that exhibits all the necessary qualities for 
this function is polyurethane. 
 Polyurethane has an extensive history dating back to 1937 when Otto Bayer’s team 
discovered the first polyurethane synthesis reaction. The first biomedical application of 
polyester-urethane foams was used for breast implants by Pangman in 1958. Also in 1958, 
Mandrino and Salvatore used rigid polyester-urethane foam called Ostamer for bone fixation. 
Initially, cardiovascular applications of polyurethane did not yield favorable results due to its 
Figure 7: SEM images comparing electrospun polyurethane (bottom) to ECM (top).35  
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hydraulic instability. Further research explained that all polyurethanes could not be categorized 
as one major class of material, but rather the properties of the polyurethane depend on many 
factors including chemistry and manufacturing.36  
 The properties of polyurethane may differ depending on the type of polyurethane and the 
processing mechanism but generally, all polyurethanes have some common qualities. One 
particular study on polyurethane proved that even after 42 days, cells had over 90% viability on 
the polyurethane scaffold and there was never enough change in the DNA structure of the cell to 
be statistically significant.37 Studies have also shown that polyurethane supports cardiomyocyte 
gap junction formation.38 In regards to the biocompatibility of polyurethane, studies have shown 
that polyurethane does not induce cytotoxicity. Furthermore, polyurethane does not release 
cytotoxic contaminants when degrading or interacting with its surroundings.39 Polyurethanes 
have also exhibited positive results when testing blood compatibility.36 
 The mechanical properties of polyurethane also make it an attractive material choice for 
use as a scaffold material. Although the mechanical properties of electrospun polyurethane vary 
depending on the conditions under which it was created, polyurethane generally exhibits good 
mechanical strength while maintaining flexibility. Polyurethane is available in two major classes, 
thermoplastics and thermosets. For the purpose of scaffolding design, thermoplastic polyurethane 
has more desirable qualities. Mechanically, thermoplastic polyurethanes are elastomeric, 
meaning, it will return to its original shape when flexed. Furthermore, thermoplastic 
polyurethanes are resistant to microorganisms, which will help with the biocompatibility of the 
scaffold. They also have a high level of hydrolytic stability.40 However, while there are many 
advantages to using polyurethane as a scaffold, one of the major challenges is the fact that the 
material used for the biological pacemaker would need to be extremely thin so as to allow gap 
junction formation across the scaffold. At such thicknesses, the material is very flimsy and would 
likely need to be reinforced in some way.  
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 Atherosclerosis, a condition in which the arteries are clogged with plaque, is typically 
treated using a minimally invasive procedure called angioplasty. This procedure uses a catheter 
with a deflated balloon on the tip which is inserted into the vasculature and guided to the site of 
the plaque buildup. Once it is in the correct location, the balloon is inflated pushing the plaque 
back against the wall of the arteries thus improving blood flow. The balloon is subsequently 
deflated and removed. According to the American Heart Association, stents are used in 
conjunction with angioplasty roughly 70% of the time. A sent is essentially a mesh tube that is 
placed on the tip of the catheter over the balloon. As the balloon inflates inside the blood vessel, 
the catheter is forced to expand. As the balloon in deflated and removed, the stent remains in its 
expanded form and remains in the blood vessel permanently acting as a sort of scaffolding to 
hold the vessel open.  
 Although all cardiovascular stents traditionally the serve the same basic purpose (to 
provide structural support to compromised blood vessels) there are many different types of 
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stents. The two major classifications of cardiovascular stents. The first includes bare metal stents, 
the original type of stent introduced in 1986. These are typically made of stainless steel but many 
other metals, alloys and polymers can be used such as gold, titanium, cobalt-chromium alloys 
and titanium alloys, to name a few. The second class includes drug eluting stents which are 
basically bare metal stents with a drug coating. The drug is released over the course of a few 
months in an effort to prevent the vessel from reclosing.  
 Although cardiovascular stents are typically only used in the treatment of atherosclerosis, 
they have potential for use in other applications requiring a similar type of support structure.  
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Chapter 3: Project Strategy 
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 Design a biologically inert device that restrains cells from moving from the implantation 
region in the heart while also allowing them to form cell to cell junctions. 
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• Scaffold should be permanent 
• The total cost should not exceed $524.00 
• Endovascular implantation  
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• Scaffold should prevent hMSC migration away from target location 
• Scaffold should prevent hMSC migration out of the scaffold 
• Scaffold should allow gap junction formation between the hMSCs and myocytes  
• Scaffold should allow functional gap junction formation between hMSCs and myocytes 
• Scaffold should not impede electrical activity of the native cells 
• Scaffold should not impede electrical activity of hMSCs 
• Implant without any damage to the scaffold 
• Scaffold should minimize damage to the heart during implantation 
• Scaffold can withstand contractile forces of the heart 
• Scaffold should be able to withstand cyclic loading of the heart 
• Scaffold should have attachment mechanisms 
• Scaffold should not move except to comply with normal mechanical function 
• Scaffold should be compliant enough to minimize decreases in regional mechanical 
function 
• Scaffold size and shape should minimize interference with the mechanical function of the 
heart 
• Scaffold size and shape should minimize interference with the electrical function of the 
heart  
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• Pore size must be less than 3 !m 
 
In order to determine an adequate pore size range for the electrospun polyurthenane fiber it is 
important to determine the typical size of a mesenchymal stem cell. Extensive literature searches 
yielded limited results with significant variation. The summarized results from the literature 
searches proceed. In a study titled ‘T cell responses to allogeneic human mesenchymal stem 
cells: immunogenicity, tolerance, and suppression’ the group stated the average size of the 
hMSCs they worked with were 30 !m in diameter.41 However, beyond simply stating this figure 
the study provided no additional information. Another study by Toma et al.  titled ‘Fate Of 
Culture-Expanded Mesenchymal Stem Cells in The Microvasculature: In Vivo Observations of 
Cell Kinetics’ stated that the average rat MSC size was around 23.6 ± .7 !m.42 The study also 
noted that freshly isolated hMSCs had a smaller size than rat MSCs at around 10 !m. This figure 
was cited from a 2003 study titled ‘Molecular and cellular characterisation of highly purified 
stromal stem cells derived from human bone marrow’. Interestingly a review of this cited article 
yielded no such specification of hMSC diameter.43 The Toma et al. paper went on to state in the 
supplemental materials section that they used a polycarbonate filter in their study with a pore 
size of 10!M to be lower than the minimal cell size of the rat MSCs.  
The previous MQP team referenced an article titled ‘Parathyroid hormone improves contractile 
performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way’ 
where they concluded “a [MSC] cell has a length of 10.0µm and a thickness of 2.0µm”. 
However, we are hesitant to use such a characterization because after review of the cited study 
no such figures were reported. In fact, the authors only provided raw data of a control group of 
cells (rat cardiomyocytes) where it can be estimated from the graphs that ‘cell length’ is around 
100 !m and ‘cell width’ is around 26 !m.44 
The most conclusive research found on the size of mesenchymal stem cells comes from 
Majore et. al in a paper titled “Identification of subpopulations in mesenchymal stem cell-like 
cultures from human umbilical cord”. Based on this study of various subpopulation of cells it 
was concluded the average cell diameter was 15 ± .8 !m. However, this figure is based on the 
average of subpopulations which themselves had averages ranging from 11 to 19 !m.45  
Based on the discussed results we speculate that a pore size of around 5 !m should contain the 
MSCs. However, this estimation is theoretical in nature. There are other factors that will 
determine the ultimate pore size such as ability for the cell to deform and squeeze through the 
pores, as well as deflection due to the contractile forces of the heart. Experimental data from the 
previous MQP team initial pilot studies to investigate cell migration through the scaffold. In a 
cell migration assay it was determined that a pore size of .4-3 !m would contain hMSCs. We 
have decided to use this specification. 
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• Scaffold should be able to withstand a minimal cyclic force of 32 kPa and resist fatigue 
for at least 3.7 x 108 cycles 
 
The fatigue strength of the scaffold is related to the duration of the implant. Consider an 
implant that is to be implanted for at least 10 years. If the average heart rate of an adult is taken 
to be 70 beats per minute, this results in 36,792 ,000 beats.46 For a 10 year period this yields 
nearly 3.7 x 108 cycles. Additionally consider, that the average systolic pressure of the heart is 
120 mmHg or roughly 16 kPa.47 If designed with a safety factor of 2, then the scaffold would 
need to withstand at least a force of 32 kPa under cyclical loading for at least 3.7 x 108 cycles. 
• Gap junction formation should occur within a minimal time period 
 
The previous MQP had stated that “gap junctions should be able to form within 48 hours”. 
However, there was no justification or explanation for this specification.  
Though gap junctions are integral membrane protein, they do not have a long half-life (>20 
hours) as might be expected. Instead, research in many different cell lines has indicated the half-
life for the connexin proteins, which form the gap junctions, to range from 1.5 to 4 hours.48 What 
this indicates is a fast turnover speed, and that should the scaffold allow for cellular contact 
through the pores, gap junctions will be produced at a rate determined by the biochemical 
conditions. It is therefore difficult to establish a specification for a maximum time for gap 
junction formation. Such a time frame is not indicative of the capacity of the cells to form gap 
junctions but rather indicates if the scaffold itself physically allows gap junction formation. 
Perhaps, an experiment can be designed that can determine a time frame for expected gap 
junction formation, therefore if gap junctions have not formed after the allotted time it signifies 
failure of the scaffold to permit gap junction formation. For example, an experiment could be 
done using a porous scaffold with MSCs on one side and myocytes on the other. The experiment 
can be run in duplicates, and then stained at various time points (such as 30 min, 1 hr, 2hr, 4hr, 
etc.) to determine the time needed for gap junction formation. At this time there are no plans for 
such an experiment. 
 
• Scaffold size and shape should allow for the seeding of at least 700,000 live hMSCs  
 
Based on a previous interview with Dr. Ira Cohen of the Institute of Molecular Cardiology at 
SUNY Stony Brook he stated that his team estimates that 350,000 modified MSCs are needed to 
restore electrical function. However, with a transfection efficiency of 50% it is necessary to use 
700,000 cells. Therefore the scaffold must allow the containment of this many cells. 
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• Scaffold should not degrade within 10 years of implantation 
• Scaffold should not detach from implant location 
• Scaffold should not elicit an immune response  
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• Scaffold should not induce inflammation  
• Scaffold should not cause scar tissue formation  
• Scaffold must be compatible with life.  
• Scaffold must be implantable via minimally invasive surgery (not requiring the opening 
of the thoracic cavity)  
• Scaffold should be biologically inert 
• Project must be completed by April 14, 2010 
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• Must be autonomically responsive to physiological changes 
• hMSCs will not proliferate after transfection 
;&4,5&*'80,&)"'!"("&:&)"'
 Design a permanent, biocompatible scaffold to contain HCN2 transfected human 
mesenchymal stem cells (hMSCs) that allows gap junction formation through the scaffold 
between hMSCs and the neighboring myocytes. Scaffold should not interfere with the normal 
functions of the heart. Implantation of the scaffold should be minimally invasive and minimize 
damage to the scaffold and the heart tissue. Ultimately, the device will act as a pacemaker to 
restore the natural electrical activity of the heart. 
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 To begin the design and development process our team conducted extensive background 
research regarding all aspects relevant to the project including biological pacemakers, scaffold 
material and design. We then took a magnified look at the initial and revised client statements 
and detailed objectives, functions, specifications, constraints and assumptions of the project. 
Through evaluative measures such as pairwise comparison charts and client interviews, we 
determined which functions were more important to incorporate compared to others and starting 
creating conceptual designs. 
 From the conceptual design phase we completed further analysis of the logistics of each 
idea and narrowed our choices to a few preliminary designs. The specifications of these designs 
were then detailed and each design was compared to one another using additional evaluative 
tools. Using the synopsis of these analyses a final design was chosen and feasibility testing and 
research ensued. Further design verification was completed on the final design through various 
experiments that quantified the results. Cross-referencing the lists of objectives, functions and 
constraints also showed whether the ultimate design encompassed all the original goals.  
 All the while, we completed verification testing on other aspects of the design, not 
necessarily including the actual final design, in order to prove the validity of our theories. The 
ideas we were trying to prove include mechanical testing of the polyurethane to ensure that it 
was capable of withstanding the forces of the heart and migrational assays to ensure the hMSCs 
would remain contained within the polyurethane scaffold. 
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Chapter 4: Alternative Designs 
 The revised client statement (discussed in the previous chapter) states that the goal of this 
project is to create a permanent, biocompatible scaffold to contain hMSCs while allowing them 
to form gap junctions with myocytes on the other side of the scaffold. In order to design this 
device, the group needed to come up with some potential mechanisms to accomplish the 
functions and objectives that follow from this client statement. Once several conceptual designs 
were suggested, we needed to decide exactly what the requirements of the design we in terms of 
specific shape, size or manufacturing restrictions. These restrictions served as a metric used to 
determine whether we should continue investigating a conceptual design or not.  
 In addition to determining our needs, we also needed to conduct a feasibility study. This 
is incorporated in this chapter and includes a discussion of research and testing that would need 
to be done to ensure that each aspect of the design is conceptually sound and then to validate the 
design before it would be able to transition into the clinic. There are many limitations placed on a 
Major Qualifying Project including time constraints, budget constraints and limited resources, 
and as a result, there are many crucial steps in validating the design that cannot actually be taken 
given the scope of the project. Still, these aspects of the project are well-worth investigating and 
thoroughly discussing. Taking into account the feasibility study, three or four preliminary 
designs could be chosen from the conceptual designs. Finally, this chapter details all of the 
decision making and optimization processes that took place from the conceptual design phase 
through the final design phase.  
)87,#6(=&2$A#0+>70$
 One of the most effective tools the team used in developing conceptual designs was a 
Morphological Chart. This approach allowed us to focus on brainstorming means to accomplish 
one function at a time, as opposed to trying to come up with an entire design that accomplishes 
all of our functions at the same time. This chart can be seen on the next page. 
26 
 
Table 1: Morphological Chart 
Functions Means 
Shape 
“Football” 
shaped 
Hollow/solid 
tube 
Rolled up sheet 
into a “yoga 
mat” 
 
“Donut” 
shaped 
Coil or 
spiral Crescent 
Sandwich-
something with 
multiple layers Sphere Pouch 
Structural integrity  
(over time) Ribs Exoskeleton Mesh material 
      Structural integrity  
(during delivery) 
Protective 
coating 
Degradable 
capsule 
       
Closure method 
Drawstring 
method Bioglue Sutures 
Vacuum 
sealer 
(crimp) 
Plug 
method 
    Cell insertion Injection Seeding 
       
Attachment method None Staples Sutures 
Sewing 
cuff 
     Post-delivery 
deployment 
Umbrella 
deployment Stent 
Self-expanding 
stent Inflatable 
     
Delivery route Endovascular Epicardial 
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 After several means were developed to address each function, these ideas were used to 
develop slightly more detailed conceptual designs. Some of these are depicted below.  
 
Figure 8: Water bag design 
This water bag design incorporated the pouch idea, which would contain 
the cells. The main feature of this design was the injectable port for the 
cells. This allowed an interesting injection method that coupled as a way 
to close off the device after cell insertion.  
 
 
Figure 9: Crescent shaped design 
This design took the crescent shape as the 
main part of the design for it’s increased 
surface area. The main feature of this design was the support 
structure, which can be seen by the darkened line in the center of 
the device. This would allow for the device to have some sort of 
framework from a sturdier material. The polyurethane could then 
be spun onto the framework and the cells seeded on.  
 
Figure 10: Donut design 
This view of the design is from the top 
so it should be noted that the design is not flat but rather rounded on 
the sides, much like a donut is. The main feature of this design is the 
increase surface area due to the top, bottom, sides and middle being 
exposed to the implant location. Also, the device is meant to have a 
mesh layer that was a different, slightly more structural material for 
mechanical integrity.  
 
 
 
 
 
Figure 11: Spiral shaped design 
The image on the left is the top view of 
this design and the image on the right 
is the side view of one coil. This 
design was considered due to the increased surface contact of each coil with the implant location. 
This aspect of the design made it desirable due to the increase area for the cells to form gap 
junctions with the myocytes.  
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Figure 12: Chinese lantern design 
The idea here would be to electrospin the polyurethane around a shape memory material in the 
form of a rod. Once it is implanted it would expand into a sphere, like a cage with the 
polyurethane stretched over it. The advantages of this design include the support structure and 
the increased surface area.  
 
 
Figure 13: Tube design 
This idea is very simple with polyurethane electrospin around a rod and taken off with the cells 
seeded on the inside. It could also have a solid center that the polyurethane would be wrapped 
around. The ends could be tied off in this design. The advantages of this design are the ease of 
manufacture and the increased contact with the implant location.  
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Figure 14: Double sandwich design 
This design was made of many 
layers—the outside would be 
electrospun polyurethane and the 
middle layer would be a scaffold made 
with a sturdier material. The cells 
would be seeded in between the 
scaffold and the polyurethane. This 
design also provides and increased 
contact area for the cells as well as a 
central support structure for 
mechanical integrity.  
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Table 2: Decision Matrix 
 
We then took the conceptual designs and crossed them with main functions to see which 
designs matched our criteria the most. This information can be seen in the table above.  
Designs ! 
W
at
er
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ag
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re
sc
en
t 
D
on
ut
 
Sp
ira
l/C
oi
l 
C
hi
ne
se
 
la
nt
er
n 
H
ol
lo
w
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ol
id
 
Tu
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es
ig
n 
Sa
nd
w
ic
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Function " 
Prevent hMSC 
migration out of scaffold 
Y Y N Y Y Y Y 
Allow functional gap 
junction formation 
Y Y Y Y Y Y Y 
Not impede electrical 
activity 
Y Y Y Y Y Y Y 
Implantable without 
damage to scaffold 
Y N Y N N Y Y 
Minimize damage to 
heart 
Y N Y N N Y Y 
Withstand contractile 
forces of the heart 
Y N Y N N Y Y 
Withstand cyclic loading 
of the heart 
Y N Y N N Y Y 
Should not move except 
to comply with normal 
heart function 
N Y N Y Y Y Y 
Ease of manufacture N N N N Y Y Y 
Good potential for 
delivery 
N N N N Y Y N 
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The functions we considered in the decision matrix were narrowed down to the major ones that 
affected our decision-making. We also added two criteria that were heavily considered when 
making our decision: the ease of manufacture and what the potential for delivery was like. When 
the functions were crossed with our conceptual designs, we were able to narrow our ideas to the 
“Chinese lantern design,” the hollow or solid tube design, and the sandwich design. These 
choices were made based on the fact that these designs met most of the major criteria. Even at 
this point though, the conceptual designs were in no way finalized.  
 At this point we decided to use a pairwise comparison chart to further analyze our 
function to rank them according to level of importance. We also wanted to learn which functions 
were most important to the clients, Glenn and Matt. The completed pairwise comparison chart 
can be seen below.  
 
Table 3: Completed Pairwise Comparison Chart
 
The rankings of the functions in order of importance with collective input can and client-
only input can be seen below:  
 
Collective Ranking 
1. Prevent hMSC migration 
2. Minimize electrical interference 
3. Minimize mechanical interference 
4. Minimize inflammatory response 
5. Withstand contractile forces  
6. Withstand cyclic loading 
7. Minimize scar tissue formation 
8. Removable 
Client-Only Ranking 
1. Prevent hMSC migration 
Functions Glenn Matt Sam Keeon Kush Bhavika 
Client 
Avg. 
Total 
Avg. 
Prevent hMSC migration from scaffold 7 7 7 7 7  7 7 7 
Minimize scar tissue 6 0 2 2 3  2 3 2.5 
Minimize inflammatory response 5 4 2 1 3  5 4.5 3.3 
Minimize mechanical interference 3 5 1 6 4  4 4 3.8 
Minimize electrical interference 8 4 6 5 6  6 6 5.8 
Removable 3 4 1 0 0  0 3.5 1.3 
Withstand cyclic loading 3 1 4 4 2  1 2 2.5 
Withstand contractile forces of heart 0 3 5 3 3  3 1.5 2.8 
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2. Minimize electrical interference 
3. Minimize inflammatory response 
4. Minimize mechanical interference 
5. Removable 
6. Minimize scar tissue formation 
7. Withstand cyclic loading 
8. Withstand contractile force 
 The major difference was that the clients ranked removability higher than the collective 
ranking and withstanding contractile forces lower than the collective ranking. Most other 
rankings were within one place. We took this information into consideration when narrowing our 
conceptual designs down to preliminary designs. We also started making adjustments to our 
conceptual designs to add more details that would transfer to the final design, if that idea were to 
be selected.  
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 In addition to the decision matrix and the pairwise comparison charts, there were also 
other requirements that we needed to consider as we began working to reduce and combine the 
conceptual designs into a handful of preliminary designs. In order to be able to do this, we 
needed to think about the clients and the users of our device and determine what the specific 
requirements are.  
The device must be no wider than 3 mm.  
 Some of the first things to consider when we were narrowing down our potential designs 
were the size constraints. Ultimately, in order to be successful clinically, the device would need 
to be small enough to be implanted using minimally invasive techniques (i.e. through a catheter). 
Although there are currently no catheter systems that would be capable of delivering a device 
like this into the wall of the heart, we can conceptualize that the device could be housed inside a 
needle at the end of the catheter. The needle could then be inserted into the heart wall, leaving 
the device behind as the needle is removed. In order to accomplish this, the device must not only 
be small enough to fit inside a catheter, but also into a needle. In order to determine exactly what 
the size constraints were, we researched the diameters of standard needles. We decided that our 
device should be no wider than 3 mm, which could be accommodated by standard 11- or 10-
gauge needles which have diameters of 3.048 mm and 3.404 mm respectively.  
 In addition to how the device was going to be implanted, we also needed to consider 
where the device was going to be implanted. The thickness of the average adult ventricular 
septum is about 8.8 mm. Thus, we decided that a size limit of 3 mm for the width was 
acceptable.  
The surface area available for cell seeding must be at least 100 mm2.  
 Based on the experience of personnel in Professor Gaudette's lab, we assumed a cell 
seeding density of 2,000 hMSCs per mm2. Also based on the recommendations of Professor 
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Gaudette and his colleagues, we assumed that 200,000 cells will be required to create an 
adequate current to restore pacemaker function (this assumption will be discussed in more depth 
in the following section of this chapter). Based on these factors, we can calculate that the area 
required for gap junction formation across the surface of the scaffold must be at least 100 mm2.  
The electrospun scaffold material should be around 40 µm thick.  
 The objectives and functions for the project specify that the scaffold must be capable of 
containing the hMSCs but thin enough to allow them to form gap junctions with myocytes on the 
other side of the scaffold. Based on the electrospinning experiences of BioSurfaces, Inc. and the 
previous work of Professor Gaudette, we hypothesize that the thickness of the scaffold will need 
to be around 40 µm thick. We planned to test this hypothesis through experiments to test 
different thicknesses of materials to determine the thinnest possible material that will still 
prevent migration of the hMSCs through the scaffold. Based on the results of this experiment, we 
planned to come up with a more precise determination of the necessary thickness by testing to 
see which thickness will allow gap junction formation. The protocols for these experiments can 
be found later on in this chapter, followed by results in the following chapter.  
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 As with most engineering projects, there came a point where we needed to determine if 
the basic concepts upon which our device is based are actually valid and if each aspect of the 
device is feasible. A lot of this was addressed in the initial research that the project required and 
is included in the literature review. However, there are several aspects of the project that have yet 
to be addressed, several of which our group does not have the capabilities to directly investigate.  
 One of the primary constraints is budget. Our group is currently working within a budget 
of $1,024, and considering the fact that a single vial of hMSCs can cost upwards of $500, it's 
easy to see that such a limited budget doesn't go as far as we would like. In addition to monetary 
resources, we also don't have access to many of the resources necessary to validate several 
aspects of our project. For instance, we don't have access to an electrospinning machine so we 
are very limited in the amount of electrospun scaffold material that we have to run experiments 
on. On top of the limited resources available, time constraints are also a factor. In general, 
medical devices can take decades to develop from the time the idea is conceived to the time they 
are actually available to patients. In contrast, our project needs to take place within nine months. 
It is unreasonable to think that we would be able to address every single aspect of the project that 
will eventually need to be addressed before a device like this could transition to the clinic.  
 Still, even those parts of the project that we are unable to directly examine are crucial to 
the overall success of the project, and they are worth discussing in more depth.  
It will be necessary to perform further characterization of the HCN modified hMSCs.  
 Much of what we know about the HCN modified cells is from unpublished data from 
Glenn Gaudette and his colleagues. While a lot of work has been done to research the properties 
of these cells, there is still a lot of speculation. For instance, the number of cells necessary to 
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create an adequate action potential is still a very theoretical number. It is based on even more 
unpublished data, personal experiences of Professor Gaudette and his colleagues, and 
mathematical models. Originally, our group was working under the assumption that it would be 
necessary for our device to contain 700,000 cells, a number used by the previous MQP team 
working on this project given to them via email by Dr. Ira Cohen. Recently, however, it has been 
suggested that as few as 10,000 cells are sufficient. Due to the fact that our group is unable to 
work with these modified cells, we decided to use 200,000 cells. However, further work must be 
done on the cells in the future if this device is ever going to make it market.  
 Furthermore, unpublished reports of researchers who have a lot of experience working 
with these cells report that the cells stop proliferating after they are transfected with the HCN 
gene. This is beneficial because once they are encased in our device it is crucial that they do not 
proliferate and over-crowd or even rupture the device. However, the transfection efficiency is 
currently another highly theoretical number. It has been reported to us that the transfection 
efficiency for these cells is around 50%, and although that number is getting better all the time, it 
still presents several problems. One of the major problems is the fact that we need to be able to 
separate the transfected cells from the non-transfected cells. This is necessary for two main 
reasons. First, we need to device to be as small as possible so we don't want non-transfected cells 
taking up any of the valuable scaffold because they are not functional. The minimum number of 
cells required to create an action potential only includes transfected cells. Thus, without a way to 
sort functional cells from non-functional cells the scaffold would need to be twice as big to 
account for the 50% transfection efficiency. Secondly, and more importantly, the cells that are 
not transfected do not stop proliferating. If these cells were seeded into the device and implanted 
into the body, they would likely continue to proliferate until the electrospun scaffold ruptures 
releasing all of the cells, transfected and non-transfected, which have the potential to create 
problems in other areas of the body.  
 In addition, while it's one thing to design a device, actually manufacturing the device is 
something else entirely. Particularly, the fact that we are using an electrospun scaffold presents 
some specific challenges. First of all, even if the parameters for electrospinning are kept the 
same, the thicknesses of the materials are often inconsistent. Since our device is dependent on a 
very precise thickness of the scaffold, this will need to be addressed before our device can be 
manufactured on a large scale. Also, we used polyurethane that had been electrospun into sheets 
for all of our experiments, however when our device is being manufactured the polyurethane will 
be spun into a tube-like shape.  After we determine the thickness of the material necessary, we 
will need to adjust the electrospinning parameters to give us the same thickness of a very small 
tube as opposed to a large sheet. Since our group does not have access to an electrospinner, this 
is difficult for us to characterize at present.  
 Furthermore, if our design involves a shape other than a cylindrical tube or a sheet, 
previous experience tells us that this will exacerbate the unevenness of the electrospinning. This 
will also need to be addressed. It was recently brought to our attention that a polymer blend (such 
as PU/PET, perhaps) could create a more evenly distributed electrospun material. However, 
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since all of the materials we have worked with so far have been purely PU, our group decided to 
continue working with PU alone for the duration of this project. We would recommend that a 
polymer blend material be examined as an option in the future.  
 In addition to electrospinning, there are other aspects of manufacturing that complicate 
the process. After the device is electrospun, the cells must be seeded onto the device. Since the 
device is so small, this process will need to be developed and optimized. Finally, after the cells 
are inserted into the device, it will need to be closed off to ensure that the cells will not be able to 
escape the scaffold.  
 Antoher aspect of the design that was out of scope for the time period of this project was 
the incorporation of a drug into the material or as a coating that prevents or limits the foreign 
body response. Certain drugs could be cross-linked with the sheath material (polyurethane or a 
polyurethane blend) that could serve as protective measures against inflammation, scar tissue 
formation and immune responses to implantation. When considering this possibility, there are 
major barriers to consider. If the drug was going to encapsulate the whole device, an important 
feature to consider is how fast the drug degrades to ensure the hMSCs can receive nutrients from 
the surrounding area.  
Implantation 
 Implanting the device is another component of the device that requires further research. 
There are limited studies available regarding the best location for this device, many simply 
focusing on ventricular pacing. Further research should be completed to understand which 
locations in the heart would be better to treat certain problems. The actual method of delivery is 
another aspect that requires a great deal of additional research. In the early design stages of this 
device, a catheter delivery system was conceptualized as the ultimate delivery vehicle. However, 
in order for this delivery system to function, it would be essential to consider whether the device 
could withstand the shear stresses of moving through a catheter.  
Characterization of mechanical properties 
 When the details of the design start becoming more finalized, it is important to 
characterize the mechanical properties of the device itself as well as the environment it would be 
implanted in and delivered through. To complete thorough testing, scaled prototypes would be 
necessary which would be expensive. On the actual device, the properties of both the wire and 
the sheath would require characterization. Internally, the intramuscular forces of the septum 
would require characterization to understand the physical environment that the device would be 
placed into. Furthermore, the effect of cyclic loading over time would be an important factor to 
consider for this device to ensure long-term functionality.   
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 After considering all of the above, we began developing our preliminary designs and 
evaluating them against all the criteria. A description and list of advantages and disadvantages of 
each of the preliminary designs we chose can be seen below.  
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Chinese Lantern 
This design entails polyurethane electrospun onto some sort of shape memory material in the 
form of a rod that would expand to a cage-like structure.  
Advantages:  
• Delivery could potentially be minimally 
invasive using an existing catheter based 
system 
• May not require any attachment 
mechanism  
• Good mechanical support 
• Allows for a variety of closure 
mechanisms 
 Disadvantages: 
• May be difficult to manufacture 
• Shape may not be well suited for delivery into the septum  
• May not be the optimal shape for the greatest surface area 
• Removal may be complicated 
 
Sandwich Design 
The sandwich design would have a middle scaffold layer and 
electrospun polyurethane on the outsides with hMSCs seeded 
in between.  
Advantages: 
• Allow gap junction formation by having a 
layer on both sides of hMSCs 
• Choice of middle material can be used to 
adjust strength and compliance of the 
scaffold 
• Could be drug-coated to help reduce inflammation 
Disadvantages: 
• Middle layer would have to be carefully chosen 
• May need to be used as a patch because delivery of this shape into the septum 
may be difficult 
• Device would be difficult to remove 
!
!
Figure 15: Chinese Lantern Preliminary 
Design 
Figure 16: Sandwich Preliminary Design 
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Solid or Hollow Tube 
Depending on whether the polyurethane tube would be spun onto a scaffold 
or left hollow, the tube idea consists of an outer layer of polyurethane.  
Advantages: 
• Shape would be flexible  
• Solid design allows for structural support 
• Scaffold shape and size minimizes scar tissue formation  
Disadvantages: 
• Delivery may be difficult 
• Hollow tube may not have enough 
mechanical strength and shear stress capacity 
 
 Stent Spun Design 
This design was not one of the conceptual ideas but rather 
was a modification of the solid or hollow tube design The 
change here is that the polyurethane would be directly 
electrospun onto the stent with the cells seeded on the 
inside.  
Advantages: 
• Stent provides flexibility, support for the 
scaffold 
• May have delivery mechanism through 
catheter based system 
• Biocompatible (PU + existing stent material) 
Disadvantages: 
• Closing off the ends poses a challenge 
• Catheter delivery may interfere with the seeded interior 
• Sealing the ends would require delivery mechanism different from current stent 
delivery 
• Amount of surface area for hMSCs in 
the unexpanded interior is limited  
 After further consideration, the stent spun 
design also gave way to a few more design 
alternatives. We originally chose this design as our 
"final design" but when it came time to perform 
Figure 17: Solid or Hollow Tube Preliminary Design 
Figure 18: Stent Spun Preliminary Design 
Figure 19: The "Double Helix" variation of 
the Stent Spun preliminary design. 
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validation experiments we had a very hard time acquiring a stent. This forced us to look for 
alternative methods of providing shape, support and flexibility to the scaffold. We examined 
many other forms of metal support structures including various meshes (such as a material 
resembling a window screen from the hardware store) and stent-like structures that we could 
potentially manufacture. We also came up with the idea to use a compression spring; it would be 
supportive yet flexible and have the capabilities of complying with the motions of the heart. 
However, we were worried that the spring would not be supportive enough to facilitate delivery 
of the device. We determined that a possible solution to this problem would be to use two 
springs, and we based our double helix variation of the tent spun design off of this concept.  
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 After further consideration of the double helix design, it became obvious that a cylinder 
was not the optimum shape for something that was going to be implanted into the ventricular 
septum.  To solve this problem, we wanted to do something along the lines of "squishing" the 
spring, so instead of being a cylindrical spring it would be more like an elliptical spring. This 
would allow the device to fit more easily into the septum.  
 Once we determined the shape of the device, we 
needed to determine the dimensions. As listed previously in 
the chapter, the device cannot be any wider than 3 mm, so 
we determined that the widest part of the ellipse must be 3 
mm. We then chose the height of the ellipse to be 1 mm. 
With these dimensions set, we then needed to determine 
how long the elliptical spring must be to yield enough 
surface area for the 200,000 cells. These calculations are 
shown below:  
 
Surface area required for 200,000 cells:  
 !!!!!!!"##$!! !! ! !!""!!!!!!"##$!  !!!!!!!"##$ ! ! !""!!!!!!"##$ !! !!  ! ! !""! !! 
 We then used the surface area required of the cells as the surface area of the cylinder, 
taking into account the fact that the wires of the springs would take up roughly 20% of the 
surface area. This means that the actual outer surface area of the spring would need to be 120 
mm2. Using this number and the dimensions of the cross-section listed above, we worked in 
reverse to calculate the necessary length of the frame. It should also be noted that we used a 
model in SolidWorks that was in the shape of a slot instead of an ellipse to simplify the 
calculations. A slot essentially consists of a rectangle with a semicircle on either end (shown 
below with the calculations to determine the length needed).  
1 mm 
3 mm 
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Length of device to achieve a surface area of 120 mm2: 
 !!!!" ! !!! ! !"#! !! !!!!!!!!!! !!!!! ! !"#! !! !!!!!"! !! ! !"#! !! ! ! !"!!! ! ! !!!"!!" 
 
To be conservative, our group decided on a length of 1.7 cm.  
 
 Once the size of the device was set, 
we needed to determine the materials. We 
already knew that  the electrospun material 
on the outside of the double helix frame was 
going to be polyurethane, although we do 
recommend looking into using a polymer 
blend in the future. Next, we needed to 
decide on a material for the frame. In order 
to do that we started off by looking into 
materials that stents are most frequently 
made out of, and the two most popular and 
most successful materials were stainless steel 
and nitinol. The chart to the right highlights 
some of the properties of each material. This 
was one of the tools we used to decide which 
material was better suited to our application.  
 Nitinol's mechanical properties, (including a relatively low Young's modulus, moderate 
radial strength and ultimate tensile strength, and relatively high flexibility) make it an ideal 
material for our application. In addition, it is highly biocompatible and corrodes far less than 
stainless steel which is extremely important attributes of a material that will ideally be 
permanently implanted into the body. Although a nitinol frame may be more difficult to 
manufacture and more expensive, we believe that these are two of the less important 
considerations in choosing a material for a device. Thus, our group decided upon nitinol as the 
material for our double helix frame.  
   316L Stainless  
Steel 
Nitinol 
Young’s Modulus  Medium Low 
Radial Strength  High Medium 
UTS  Low Medium 
Flexibility  Low-Medium High 
Corrosiveness  High Low 
Biocompatibility  Low High 
Manufacturability  High Medium 
Cost Effective  High Low 
w = 2 
mm
r = 0.5  
mm l 
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Figure 20: Double helix nitinol frame. 
 
  After the main aspects of the design were determined and the materials were chosen, 
there were some aspects of the manufacturing process that needed to be addressed. In order to 
actually produce this device, the nitinol frame must be able to be securely attached to the 
grounded mandrel for electrospinning. The frame 
must also be able to slide off the mandrel after 
electrospinning without damaging the polyurethane 
material it is now coated with. In order to address 
these problems, the group decided to design a new 
mandrel for electrospinning that would work with 
an end-cap on either end of the nitinol frame (see 
below). The crossbars on the end-caps line up with 
notches in the custom mandrel allowing the frame 
to slide partially down the length of the mandrel. A 
plug would be inserted in the notches after the 
frame to hold it in place during electrospinning. 
Once the electrospinning process was complete 
the plug could then be removed and the frame 
along with the polyurethane covering it could 
slide back off the mandrel.  
Figure 21: Representation of the end-cap on the 
nitinol frame and the notched mandrel.  
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 %
Figure 23: Nitinol double helix frame on the custom 
mandrel before electrospinning 
Figure 22: The frame would be positioned part of the 
way down the length of the mandrel to allow 
polyurethane distribution on the entire frame as well 
as on the mandrel on either side of the frame.  
Figure 24: Double helix frame on the mandrel after electrospinning.  
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One of the primary functions of our scaffold is to contain the hMSCs and prevent them from 
migrating into the surrounding tissue.  In order to characterize the proper pore size necessary to 
contain our cells and ensure that the cells are isolated within our scaffold a migration assay will 
be conducted.  The test will be conducted on polyurethane samples of 3 different spin times (30, 
45, and 60) minutes to optimize the required pore size.  Prior to testing the polyurethane will be 
soaked in 70% Ethanol for 2 hours and followed by distilled water for 2 hours. After the sample 
is left to dry in a fume hood overnight the polyurethane will be sectioned into approximately 1cm 
x 1cm pieces. Following this procedure the sections will be placed into a device known as the 
Bio-Seeder.  The Bio-Seeder is a device that will allow us to isolate the two sides of the 
polyurethane and create a proper environment to test whether the cells cross over from one side 
to other. The dimensions of the Bio-Seeder allow for it to be placed inside a well plate.  The well 
plate can then be imaged through a confocal microscope to analyze the migration of the cells. 
Approximately 50,000 cells will be seeded onto one side of the polyurethane.  There will be 
three groups of each spin time each of which will be incubated for different time periods (3, 7, 
and 14 days). The protocol that will be used to stain and test for migration is as follows: 
 
1. Remove the well insert from the well and place into another sterile well. Rinse both in 
PBS solution for 5 minutes. 
2. Remove the PBS solution and re-rinse both the well and the insert in PBS for another 5 
minutes. 
3. Remove the PBS solution. Place 4% paraformaldehyde at the bottom of the well and insert 
for a total of 10 minutes to fix the cells. 
4. Remove the paraformaldehyde and rinse with PBS solution for 5 minutes.  
5. Remove the PBS solution and re-rinse both the well and the insert in PBS for another 
5minutes.  
6. Remove the PBS solution. Place .25% Triton-X (in PBS) onto the well and insert for a 
total of 10 minutes.  
7. Remove the Triton-X and rinse with PBS solution for 5 minutes.  
8. Remove the PBS solution and rinse with 1% Bovine Serum Albumin (BSA) in PBS for 10 
minutes.  
9. Remove the PBS/BSA and place Alexa Fluor 488 Phalloidin stain (5µL Phalloidin per 
200µL PBS) on the samples for 30 minutes.  
10. Remove the stain and rinse with PBS/BSA for 10 minutes.  
11. Remove the PBS/BSA and re-rinse with more PBS/BSA for 10 minutes.  
12. Remove the PBS/BSA and re-rinse with more PBS/BSA for another 10 minutes.  
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13.Remove the PBS/BSA and place Hoechst 3342 Trihydrochloride Trihydrate stain 
(10µL/1mL Distilled Water) on the samples for 5 minutes.  
14. Remove the stain and rinse with PBS/BSA for 5 minutes.  
15. Remove the PBS/BSA and place pure PBS onto the samples. 
 
The results of this experiment can be found in the Chapter 5.  
 !
44 
 
 
Chapter 5: Results 
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 As mentioned earlier, migration assays were conducted across the polyurethane to 
characterize the appropriate thickness of the material that prevented migration of the hMSCs 
through the material.  Specially manufactured wells were used to observe the migration of the 
cells.  After the appropriate time periods had ended for the samples, (1, 3, and 7 days) the 
samples were removed from the wells and sandwiched between two slides.  These slides were 
images using an inverted fluorescent microscope; the group flipped the slides to image both sides 
of the polyurethane.  
 The results of the test showed that through the 1-day time point no cells were able to 
penetrate the 30, 45, or 60-minute polyurethane sheets.  At the 3-day time point it can be seen 
that cells are beginning to migrate through the 30 minutes sheets and still contained in the other 
two time segments.  At the final 7-day time point the cells have migrated to the other side in the 
30-minute sample.  The 45-minute sample shows promising results as the cells have not migrated 
over, however it can be seen that they are at the edge of the polyurethane sheet which would 
allow them to come in contact with cardiac myocytes in order to make gap junctions. The 60-
minute sample completely prevented migration, however the larger thickness also prevented cell 
integration into the polyurethane pores.  This could hinder the formation of gap junctions across 
the polyurethane. Figure 26 shows the results from the 1, 3 and 7 day time points for the samples 
containing FGF in the cell media. The images of the Hoescht staining are not included due to the 
autofluorescence of the polyurethane which makes it nearly impossible to see the cells (Figure 
25).  
  
Figure 25: Polyurethane autofluorescence.  
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Figure 26: Results of the Migration Assay 
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Chapter 6: Discussion 
The goal of this project was to design a biological pacemaker that could overcome the 
issues of electrical pacemakers. Challenges of autonomous biological pacing, such as cell 
migration and cell death, also had to be overcome in order to quicken the translation of this 
technology to the clinic. Our design, the BioPacer, contains genetically modified hMSCs within 
a polyurethane covered Nitinol frame. The BioPacer allows for the coupling of the stem cells 
with cardiac myocytes through carefully selected pore sizes that facilitate contact while 
inhibiting migration. The Nitinol framework of our design also gives the device both strength 
and flexibility during and after minimally invasive delivery. The biocompatibility of our 
materials, along with the size of the device and natural cardiac pacing via stem cells, allow us to 
meet our objective of creating an autonomous pacing unit that can be a permanent cure for 
cardiac patients. 
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The results of this project would not drastically influence the economy of everyday 
living, however they would significantly reduce the money spent on pacemakers each year.  A 
successful biological pacemaker is meant to last upwards of ten years and thus would not require 
repeat operations.  Previous limitations of pacemakers increased the lifetime cost due to 
replacement and reimplantation procedures. The materials used in the biological pacemaker are 
also relatively inexpensive. Polyurethane and the electrospinning procedure are both cost 
effective while Nitinol for the metal frame is becoming an increasingly common biomaterial 
which will result in less expensive manufacturing procedures.  Implantation of the device will be 
minimally invasive and the procedure will be similar to previous procedures, such as stent 
implantation, which will keep operating and training costs to a minimum.  Thus although day-to-
day costs would not be effected by our biological pacemaker, our product could significantly 
reduce the billions of dollars that are spent annually on heart related problems.   
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 The current pacemaker industry uses metal, batteries, and polymeric coatings for the 
leads.  Our biological pacemaker will be inserted into the septum and will be much smaller than 
current electrical pacemakers.  The reduced size of our device will lead to a significant reduction 
in the amount of metal used.  The polyurethane coating on the biological pacemaker will also be 
very small.  All materials used in the scaffold will stay inside the body and will not produce any 
waste or have negative impact on the environment.  Our biological pacemaker also does not have 
any electrical components, which will further reduce materials used, and also will result in no 
need to dispose of batteries.  Although our project does not have direct environmental impacts 
the size and design of our product will not result in any adverse environmental effects and will 
create less waste that harms the environment compared to current pacemakers.  
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 Our product has the potential to be a breakthrough product in the medical device 
industry.  In today’s day an age the electronic pacemaker has become a very popular and familiar 
device. Across the globe people understand the significance and clinical importance of the 
device.  It is easily considered the global gold standard to address many heart defects.  Our 
device aims to eliminate the need and thus use of such a popular device.  Such a drastic change 
has potential to impact people on a social level.  People will need to be sold on the benefits of 
this device over electronic pacemakers.  The biocompatibility, permanency, and efficiency of 
this device must be marketed to doctors, hospitals, and ordinary users for them to trust the 
product. The device’s use of stem cells must also be clarified to avoid any ethical issues that 
could arise.  Our product does not used embryonic stem cells, where much of the ethical 
controversy is focus. The use of adult stem cells does not harm any other people and can be 
taken from donors or from the client themselves.   
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 As mentioned before the product we are designing has the potential to replace 600,000 
pacemakers that are installed every year. The magnitude of such a device has great ramifications 
on the global market.  Many companies, such as Boston Scientific, have a large return on 
investment on electronic pacemakers.  A great deal of jobs and company finances rely on the 
manufacturing, marketing, and implantation of electronic pacemakers. If our product were to 
replace older pacemakers it would drastically influence the global market due to the 316.4 billion 
dollars that are spent around the world on heart disease treatments. The potential success of our 
product would not particularly change the culture of other countries.  However, the technology 
used in our product could be adapted around the world and could change the gold standard for 
heart pacing related problems.   
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With many biomedical applications harnessing the regenerative potential of stem cells 
there is always ethical concern. However, the typical arguments against using stem cells are by 
and large addressed to (human) embryonic stem cells whose harvesting typically results in the 
destruction of day old embryos. The use of hMSCs does not have the associated ethical concerns 
as these stem cells are harvested from the bone marrow of a donor and have no repercussions on 
the outcome of an embryo. Thus, in terms of ethical concern related to our product, there is 
essentially little to none, as the products sole intent and purpose is to increase patient quality of 
life. 
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As discussed, one of the key issues with conventional electronic pacemakers is the lack 
of an autonomic response to physiological changes that require increased or decreased cardiac 
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output. A biological pacemaker that can bring patients closer to the natural function of the heart 
is significantly positive influence on the health and personal safety of a person. One of the other 
concerns with using hMSCs in this application is the problems caused by uncontrolled 
proliferation and differentiation in vivo. It is a great concern to the health and safety of the 
patient that the contained hMSCs remain viable, non-proliferating, and undifferentiated. Based 
on unpublished research from Dr. Cohen it is clear that the transfected hMSCs lose their ability 
to proliferate. Researchers speculate that because the HCN channel is a key component in 
cardiac cells, hMSCs that express the protein exhibit other properties of cardiac derived cells 
such as non-proliferation. It is very important also that techniques be developed to separate non-
transfected cells from transfected ones to ensure that only hMSCs with the HCN channel are 
incorporated into the device. 
!%(31%.&3$%>"2"&,))
The manufacturability of the device depends on several components. The first is a 
consistent input of transfected hMSCs separated from non-transfected cells. Secondly the 
production of the metal frame-architecture is small scale. Initially, it will be difficult and 
potentially expensive to produce Nitinol-based architectures. Lastly, the electrospun 
polyurethane must achieve an extremely high level of quality control. The density, thickness, and 
porosity of the electrospun material must be consistent for feasible manufacturing.  
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The design incorporates components such as polyurethane and nitinol that are used in 
many commercial applications. However, in terms of sustainability there are minimal effects. 
Sustainability is only a concern in the sense that the product outlasts conventional pacemakers 
that require component replacements.  
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Chapter 7: Final Design and Validation 
 This chapter describes the task-sequence the group completed to accomplish the goals of 
the project. The purpose to help future MQP groups working on a similar project be able to 
follow a logical plan and learn the shortcomings and highlights of this project plan to use 
towards their own project.  
 The first step in understanding the project goals is taking the client statement given by the 
advisor and any sponsors and breaking it down into smaller components. Each small part of the 
client statement can then be further assessed and developed into a more detailed need. An 
important part of this process is completing client and user interviews to understand which 
objectives are most important for your device. After thorough research, the initial client 
statement has then evolved to a much more comprehensive client statement that provides 
detailed objectives for the project.  
 Once a detailed client statement has been established and approved by the advisor and 
sponsors, the next step is to establish the goals of the project. Putting these goals in writing is an 
important part of the process so the group can revisit them to ensure they are staying on task. The 
goals of the project include the objectives, constraints, functions and specifications. The 
specifications in most cases will require research to provide numerical limits for some of the 
functions trying to be obtained. For example, if a function is to meet a certain size requirement, 
the specification would be stating the size and the justification. After these goals are established, 
the group should begin thinking of their design and the background of the project.  
 The background requires completing in depth research regarding the various facets of the 
project. If a particular material is being used, this would mean researching the material 
specifications, other uses, limitations and advantages amongst other things. The initial 
background will definitely change as features are added or removed from the design and new 
developments are made. The background is continuously worked on.  
 When beginning the initial design phase, one of the most useful tools is a function-means 
tree or table. This tool requires that for every function, the group brainstorm many possible 
means to attain that possible function. If one of the functions was to close off the device, gluing 
it shut or heating it shut might attain this. After brainstorming and filling out this chart, the next 
step would be to start developing conceptual designs. 
 When developing conceptual designs, using the function-means tree is a way to 
brainstorm many different possibilities to meet your project objectives. Conceptual designs do 
not require extreme detail or explanation of the logistics, such as how would the device be 
manufactured. Instead, conceptual designs are for general ideas that could meet the preset 
objectives. To further analyze these designs, other analysis tools should be used such as a 
pairwise comparison chart filled out by the group, clients and potential users. The rankings found 
from the completion of these charts can then be cross-referenced with each conceptual design to 
see which meets the functions and objectives best. A simple pro con chart can also be used as a 
way to decide which conceptual designs have potential for further development.  
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 Once the conceptual designs are narrowed down to a few different options, experiments 
come in to play. Experiments are a way to validate the various parameters and prove that a 
certain material or design idea will in fact meet the design objective. For each experiment 
completed, the group should start by establishing the purpose of the experiment, making a list of 
the materials that will be required, actually designing the experiment and completing a schedule 
of experimental set up, execution and results analysis. These steps are essential for every 
experiment. Experiments also require anticipating things that might go wrong so that the group 
can be prepared in case something does not go as planned.  
 While completing experiments to validate various parts of the design, the group should 
also be analyzing each final design idea to start deciding which one will meet the most objectives 
and has potential for alterations and new features. Designs can be considered and altered 
infinitely so at one point, deciding on the most advantageous design is extremely important.  
 At this point in the project the experiments are being completed and the final design is 
chosen. From this point onwards, the project is about validity of the design and analysis of the 
results. Drawing conclusions from the experiments that help establish design limits is important 
as well as optimizing aspects of the design to best meet the goals initially set. All the while, it is 
important to think of limitations and recommendations for future projects to consider in the case 
that the project is continued in another year. This is one of the most important things a group can 
do because it allows for their unfinished worked to be continued without having to repeat 
experiments or certain research. Chapter 8 of this paper will describe the future 
recommendations and limitations of this project that should be addressed in future years.  
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Chapter 8: Conclusion and Future Recommendations 
 The results of the migration assay determined that a polyurethane scaffold electrospun for 
approximately 45 minutes would be effective at containing the hMSCs but still allowing gap 
junction formation. This scaffold allowed the hMSCs to migrate enough through the scaffold to 
make gap junctions connections with myocytes on the other side but prevent complete migration 
out of the scaffold. The design process the research team completed resulted in a detailed design 
that addressed many current limitations preventing biological pacemaker technology’s 
advancement to the clinic.  
 For future work, the team recommends four major steps to be taken. The first experiment 
would be to test gap junction formation through the scaffold. This experiment would validate 
that the scaffold allows the gap junction formation necessary for the biological pacemaker to 
function. The next experiment would require completing a functional assay to test that the gap 
junctions actually work and the staining is not just showing the proteins for the gap junction 
channels. This assay would be vital in the advancement of the BioPacer to the clinic. The third 
step in the research process would be to complete mechanical testing on all components of the 
scaffold to make sure each component can withstand the cyclic loading of the heart. The final 
step the research team would recommend is creating a scaled prototype of the device for further 
testing, in vivo. The research team believes that these future recommendations are necessary to 
the successful advancement of the BioPacer to the clinic.  
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Appendix A: Gantt Chart 
TASK NAME DURATION START FINISH 
Assess problem & need 6 days? Tue 9/7/10 Tue 9/14/10 
Conduct background research 16 days? Wed 9/8/10 Tue 9/28/10 
Write literature review 6 days? Mon 9/27/10 Sun 10/3/10 
Revise client statement 1 day? Tue 10/12/10 Tue 10/12/10 
Discuss Design Requirements 11 days? Mon 9/13/10 Sun 9/26/10 
Finalize Design Requirements 3 days? Sun 9/26/10 Tue 9/28/10 
Write project strategy chapter 6 days? Sun 10/3/10 Fri 10/8/10 
Generate conceptual designs 12 days? Sun 10/3/10 Mon 10/18/10 
Develop function-means tree 4 days? Wed 10/6/10 Mon 10/11/10 
Develop pairwise-comparison chart 4 days? Wed 10/6/10 Mon 10/11/10 
Develop morphological chart 4 days? Wed 10/6/10 Mon 10/11/10 
Fill out evaluative measures 7 days? Fri 10/15/10 Mon 10/25/10 
Send evaluative measures to clients 6 days Mon 10/18/10 Mon 10/25/10 
Narrow down designs by analysis 7 days? Mon 10/25/10 Tue 11/2/10 
Write Alternative Designs chapter 22 days? Mon 11/1/10 Tue 11/30/10 
Start electrospin characterization 11 days? Mon 10/18/10 Mon 11/1/10 
Mechanical testing of scaffold 22 days? Mon 11/1/10 Tue 11/30/10 
Migrational assay 22 days? Mon 11/1/10 Tue 11/30/10 
Connexin 43 staining 22 days? Mon 11/1/10 Tue 11/30/10 
Coculture on polyurethane 22 days? Mon 11/1/10 Tue 11/30/10 
Functional assays 28 days? Mon 11/1/10 Wed 12/8/10 
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Develop preliminary designs 11 days? Mon 11/1/10 Mon 11/15/10 
Analyze preliminary design choices 20 days? Tue 11/16/10 Mon 12/13/10 
Develop prototype 15 days? Thu 1/13/11 Wed 2/2/11 
Design verification testing 11 days? Thu 2/3/11 Thu 2/17/11 
Write Design Verification chapter 15 days? Tue 2/1/11 Mon 2/21/11 
Refine final design  9 days? Tue 2/22/11 Fri 3/4/11 
Write Discussion chapter 6 days? Tue 3/15/11 Tue 3/22/11 
Write final design chapter 6 days? Tue 3/22/11 Tue 3/29/11 
Write introduction 6 days? Tue 3/15/11 Tue 3/22/11 
Write conclusion & recommendations 6 days? Tue 3/29/11 Tue 4/5/11 
Write abstract & executive summary 6 days? Tue 3/29/11 Tue 4/5/11 
Work on presentation 25 days? Tue 3/1/11 Mon 4/4/11 
Work on poster 25 days? Tue 3/1/11 Mon 4/4/11 
Finalize presentation 25 days? Tue 3/1/11 Mon 4/4/11 
Finalize poster 25 days? Tue 3/1/11 Mon 4/4/11 
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